Genmab AS (CHIX:GMABC) Ending Cash Position : kr11,170 Mil (As of Mar. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Genmab AS Ending Cash Position?

Genmab AS's Ending Cash Position for the quarter that ended in Mar. 2025 was kr11,170 Mil.

Genmab AS's quarterly Ending Cash Position increased from Sep. 2024 (kr6,382 Mil) to Dec. 2024 (kr9,795 Mil) and increased from Dec. 2024 (kr9,795 Mil) to Mar. 2025 (kr11,170 Mil).

Genmab AS's annual Ending Cash Position increased from Dec. 2022 (kr10,000 Mil) to Dec. 2023 (kr15,087 Mil) but then declined from Dec. 2023 (kr15,087 Mil) to Dec. 2024 (kr9,795 Mil).

Genmab AS Ending Cash Position Historical Data

The historical data trend for Genmab AS's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Ending Cash Position Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

7,338.28

8,973.71

9,999.79

15,086.67

9,795.42

Genmab AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															14,590.80	4,310.79	6,381.54	9,795.42	11,169.97

Genmab AS Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Genmab AS's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	14772.631	+	-4977.208
	=	9,795

Genmab AS's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	9521.035	+	1648.932
	=	11,170

Genmab AS Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Genmab AS's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (CHIX:GMABc) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMAB:Mexico 0MGB:UK GMAB:Denmark GE91:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines